Actinogen Medical Ltd (ASX: ACW) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Actinogen Medical Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $65.70 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.53 billion
Earnings per share -0.007
Dividend per share N/A
Year To Date Return 19.82%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Actinogen Medical Ltd (ASX: ACW)
    Latest News

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Actinogen, Core Lithium, Fortescue, and Galileo Mining shares are pushing higher

    These ASX shares are starting the week strongly...

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Guess which ASX biotech share just rocketed 56% on new Alzheimer's drug trial results

    This biotech company is soaring ahead today.

    Read more »

    A health professional wearing green scrubs and a face mask and stethoscope uses his mobile phone.
    Healthcare Shares

    In the green: Here are the 5 best ASX healthcare shares of 2021

    ASX healthcare shares were a strong bunch last year, with several majors and minors outperforming the primary indices.

    Read more »

    Lab worker puts hands in the air and dances around
    Healthcare Shares

    Actinogen (ASX:ACW) share price surges 9% on Oxford Uni partnership

    It was a good day for the biotech company's shares. Here are the details

    Read more »

    a man clasps his hand to his forehead as he looks down at his phone and grimaces with a pained expression on his face as he watches the Pilbara Minerals share price continue to fall
    Share Fallers

    Why Actinogen, AVITA, Inghams, and NAB shares are falling

    These ASX shares are falling on Tuesday...

    Read more »

    man bending over to look at red arrow crashing down through the ground
    Healthcare Shares

    Why the Actinogen (ASX:ACW) share price is sinking 16% on Tuesday

    A clinical trial update isn't enough to draw investors in today.

    Read more »

    A group of science or medical professionals cheering good news in the lab.
    Healthcare Shares

    Here's why the Actinogen (ASX:ACW) share price is rocketing 13% today

    Yet again, news of Actinogen's XanaMIA trial has sent its shares through the roof.

    Read more »

    stock market gaining
    Share Gainers

    Why Actinogen, Novonix, ResMed, & Zip shares are pushing higher

    These ASX shares are on form on Wednesday...

    Read more »

    Vanadium Resources share price person riding rocket indicating share price increase
    Share Gainers

    Why the Actinogen (ASX:ACW) share price is rocketing 17% higher

    This biotech has been given some good news...

    Read more »

    A drawing of a white rocket streaking up, indicating a surging share pirce movement
    Healthcare Shares

    Here's why the Actinogen Medical (ASX: ACW) share price is up 20%

    Actinogen Medical shares are flying on news of the company's XanaMIA study.

    Read more »

    A woman holds a tape measure against a wall painted with the word BIG, indicating a surge in gowth shares
    ⏸️ ASX Shares

    These 5 ASX shares are delivering the biggest gains in 2021

    Bags, on bags, on bags. These ASX shares have delivered...

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Share Gainers

    Why is the Actinogen (ASX:ACW) share price up 414% in 3 months?

    This biotech company has been going gangbusters over the past year. Let's take a closer look.

    Read more »

    ACW ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Actinogen Medical Ltd

    Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

    ACW Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 May 2024 $0.03 $0.00 0.00% 2,026,350 $0.03 $0.03 $0.03
    16 May 2024 $0.03 $0.00 0.00% 2,263,820 $0.03 $0.03 $0.03
    15 May 2024 $0.03 $0.00 0.00% 2,003,462 $0.03 $0.03 $0.03
    14 May 2024 $0.03 $0.00 0.00% 1,986,208 $0.03 $0.03 $0.03
    13 May 2024 $0.03 $0.00 0.00% 1,728,899 $0.03 $0.03 $0.03
    10 May 2024 $0.03 $0.00 0.00% 2,479,242 $0.03 $0.03 $0.03
    09 May 2024 $0.03 $0.00 0.00% 3,383,842 $0.03 $0.03 $0.03
    08 May 2024 $0.03 $0.00 0.00% 6,049,689 $0.03 $0.03 $0.03
    07 May 2024 $0.03 $0.00 0.00% 2,382,480 $0.03 $0.03 $0.03
    06 May 2024 $0.03 $0.00 0.00% 2,063,927 $0.03 $0.03 $0.03
    03 May 2024 $0.03 $-0.01 -26.68% 6,157,216 $0.03 $0.03 $0.03
    30 Apr 2024 $0.04 $0.01 31.68% 8,822,657 $0.03 $0.04 $0.03
    29 Apr 2024 $0.03 $0.00 0.00% 1,912,078 $0.03 $0.03 $0.03
    26 Apr 2024 $0.03 $0.00 0.00% 2,674,332 $0.03 $0.03 $0.03
    24 Apr 2024 $0.03 $0.00 0.00% 1,147,639 $0.03 $0.03 $0.03
    23 Apr 2024 $0.03 $0.00 0.00% 1,223,032 $0.03 $0.03 $0.03
    22 Apr 2024 $0.03 $0.00 0.00% 1,570,575 $0.03 $0.03 $0.03

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Apr 2024 Malcolm McComas Expiry 3,000,000 $87,000
    Options expired.
    01 Dec 2023 George Morstyn Issued 4,500,000 $140,625
    Issued under employee share plan.
    01 Dec 2023 Geoffrey Brooke Issued 12,000,000 $375,000
    Issued under employee share plan.
    01 Dec 2023 Malcolm McComas Issued 4,500,000 $140,625
    Issued under employee share plan.
    01 Dec 2023 Steven Gourlay Issued 20,000,000 $625,000
    Issued under employee share plan.
    01 Dec 2023 Nicki Vasquez Issued 5,500,000 $171,875
    Issued under employee share plan.
    27 Nov 2023 George Morstyn Expiry 1,500,000 $34,500
    Options expired.
    27 Nov 2023 Geoffrey Brooke Expiry 4,900,000 $112,700
    Options expired.
    11 Sep 2023 Steven Gourlay Issued 2,442,647 $53,738
    Rights issue.
    11 Sep 2023 Steven Gourlay Issued 1,405,727 $35,143
    Rights issue.
    11 Sep 2023 Steven Gourlay Issued 3,479,565 $86,989
    Rights issue.
    11 Sep 2023 Malcolm McComas Issued 200,687 $4,415
    Rights issue.
    11 Sep 2023 Malcolm McComas Issued 401,372 $10,034
    Rights issue.
    11 Sep 2023 George Morstyn Issued 614,537 $15,363
    Rights issue. As per announcement on 12-09-2023
    11 Sep 2023 George Morstyn Issued 607,074 $13,355
    Rights issue.
    11 Sep 2023 George Morstyn Issued 599,610 $14,990
    Rights issue.
    11 Sep 2023 Geoffrey Brooke Issued 474,058 $11,851
    Rights issue.
    11 Sep 2023 Geoffrey Brooke Issued 512,360 $11,271
    Rights issue. As per announcement on 12-09-2023
    11 Sep 2023 Geoffrey Brooke Issued 550,661 $13,766
    Rights issue.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr George Morstyn Non-Executive Director Dec 2017
    -
    Mr Malcolm John McComas Non-Executive Director Apr 2019
    -
    Dr Geoffrey E.D Brooke Non-Executive ChairmanNon-Executive Director Feb 2021
    -
    Dr Steven Gourlay Chief Executive OfficerManaging Director Mar 2021
    -
    Dr Nicki Vasquez Non-Executive Director Mar 2023
    Dr Vasquez is an biopharmaceutical executive with more than 25 years of biopharmaceutical discovery research and development experience. Dr Vasquez is currently Chief Portfolio Strategy & Alliance Officer at Sutro Biopharma, a clinical stage oncology company in San Francisco Prior to joining Sutro, Dr Vasquez was Vice President of Program & Portfolio Management at StemCells, Inc., Earlier in her career Dr Vasquez worked at Elan Pharmaceuticals where she held positions of increasing responsibility in Alzheimers disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management. Dr Vasquez received her post-doctoral training at Genentech.
    Mr Peter Webse Company Secretary
    -
    Peter Webse Company Secretary
    -
    Michael Roberts Investor Relations
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 250,917,257 13.82%
    Dr Steven Gourlay 48,362,300 2.66%
    Edinburgh Technology Fund Limited 48,147,864 2.65%
    JSC Wealth Management Pty Ltd 44,655,962 2.46%
    Citicorp Nominees Pty Limited 38,237,380 2.11%
    Tisia Nominees Pty Ltd <Henderson Family A/C> 29,440,621 1.62%
    Garnsworthy Pension Fund Pty Ltd <Garnsworthy Pension Fund A/C> 22,000,000 1.21%
    Mr James Murch & Mrs Catherine Murch <MINJAL Super Fund A/C> 20,500,000 1.13%
    Kaleidoscope Holdings Pty Ltd <Kaleidoscope Super A/C> 20,346,473 1.12%
    SG Gourlay Nominees Pty Ltd <SF Gourlay Family A/C> 15,797,222 0.87%
    Amber Court Nominees Pty Ltd <Min Min Light A/C> 15,023,401 0.83%
    Iral Pty Ltd <IRAL A/C> 15,000,000 0.83%
    Mrs Gillian Karen Nes & Mrs Ronald Nes <GIRO S/F A/C> 15,000,000 0.83%
    Big Eater Pty Ltd <Brigitte Smith Family A/C> 12,999,659 0.72%
    John Dahlsen Superannuation Fund Pty Ltd 12,900,000 0.71%
    HSBC Custody Nominees (Australia) Limited – A/C 2 12,461,934 0.69%
    Rickenbacker Capital Investments Pty Ltd 10,400,000 0.57%
    Brazil Farming Pty Ltd 10,069,970 0.55%
    Van Am Marketing Pty Ltd 10,000,854 0.55%
    SVE Capital Pty Ltd <Strategic Vision Unit A/C> 10 0.59%

    Profile

    since

    Note